Alnylam Pharmaceuticals is launching a series of initiatives aimed at enhancing the early detection and care coordination for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The company is collaborating with Viz.ai to create an AI-driven care pathway that integrates an FDA-cleared echocardiography algorithm, Us2.ai, with electronic health records. This partnership includes the AWARE implementation study, set to begin at five U.S. health systems, which will evaluate the integration of AI screening into standard clinical workflows to generate real-world evidence for broader adoption.

These initiatives are significant as they address the critical issue of underdiagnosis in ATTR-CM, a condition that often goes unrecognized until advanced stages. By improving diagnostic processes and care coordination, Alnylam aims to facilitate timely interventions that could enhance patient outcomes.

A key takeaway for professionals in the longevity and healthspan research field is the potential for AI technologies to transform diagnostic pathways, underscoring the importance of integrating innovative solutions into routine clinical practices for better management of age-related diseases.

Source: longevity.technology